Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering
Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.
- Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the closing of its initial public offering (the Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.
- The Company received aggregate gross proceeds of $21.9 million from the Offering, before deducting underwriting discounts and other related expenses.
- Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.
- All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Companys proposed Offering.